Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL

The CORAL study highlighted the need to develop novel salvage regimens in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) previously treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Carfilzomib (CFZ) can overcome rituximab chemotherapy resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Torka, Pallawi, Groman, Adrienne, Wong, Jerry, Nichols, Jenna, Kader, Angela, Mavis, Cory, Anampa-Guzmán, Andrea, Sait, Sheila Jani, Block, AnneMarie, Przespolewski, Eugene, Mohr, Alice, Lund, Ian, McWhite, Kenneth, Kostrewa, Jessica, DeMarco, Joseph, Johnson, Michael, Darrall, Andrea, Thomas, Roshneke, Sundaram, Suchitra, Ghione, Paola, Hutson, Alan, Hernandez-Ilizaliturri, Francisco J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111346/
https://www.ncbi.nlm.nih.gov/pubmed/36375132
http://dx.doi.org/10.1182/bloodadvances.2022008543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111346/
https://www.ncbi.nlm.nih.gov/pubmed/36375132
http://dx.doi.org/10.1182/bloodadvances.2022008543

Ejemplares similares